Trial Profile
A Double-Blind Randomized Placebo-Controlled Trial of the Time to Onset of Pain Relief in Subjects With Post Therapeutic Neuralgia (PHN) Treated With Pregabalin (150 - 600 Mg/Day Flexible Optimized Dose or 300 Mg/Day Fixed Dose) or Placebo
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 04 Aug 2021
Price :
$35
*
At a glance
- Drugs Pregabalin (Primary)
- Indications Neuropathic pain; Postherpetic neuralgia
- Focus Therapeutic Use
- Sponsors Pfizer
- 01 Nov 2008 Results reported in Journal of Pain.
- 05 May 2007 Results data are available.
- 22 Nov 2006 Status change